Highlights from 7th Global Summit on Genitourinary Malignancies by DAVA Oncology

The 7th Global Summit on Genitourinary Malignancies was held at The Broadmoor in Colorado Springs, Colorado, from November 20th to 24th 2024.

This summit brought together prominent oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in the field of genitourinary cancers, including those affecting the kidneys, bladder, prostate, and other related organs. The event featured scientific presentations, panel discussions, and networking opportunities focused on advancing patient care for those with these types of cancers.

The Broadmoor GU Cancer Summit featured eight four-hour sessions with over 70 key opinion leaders. It brought together experts in prostate, kidney, and bladder cancer to discuss evolving treatment paradigms through lectures, panel discussions, and case presentations. The summit also provided a platform for fellows and junior faculty to present research, and industry representatives showcased emerging therapies. The event aimed to review and debate clinical changes anticipated in the next five years.

2024 DAVA Broadmoor GU Summit:

“Excited to kick off our 2024 DAVA Broadmoor GU Summit!  Join us as we dive into a packed agenda filled with insightful discussions. Practicing HCPs are welcome to join in through our virtual platform!”

Michael Haffner on the framework for the pathology workup of mCRPC biopsies:

“Dr. Michael Haffner kicked off the DAVA GU summit with a compelling presentation on the framework for the pathology workup of metastatic CRPC biopsies. The presentation emphasizes the need for a standardized diagnostic approach using morphology and IHC markers.

Mamta Parikh discusses the NIAGARA Phase III trial:

“Dr. Mamta Parikh discusses the NIAGARA Phase III trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in MIBC. The trial met one of two primary endpoints (EFS) and also led to extended OS​.”

Overview of TALAPRO-2 by Oliver Sartor:

“Dr. Oliver Sartor from Mayo Clinic provides an excellent overview of TALAPRO-2, a Phase 3 randomized, double-blind, placebo-controlled trial evaluating talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.”

Day 2 of the 2024 DAVA Summit:

“Good morning from Broadmoor! Join us for Day 2 of the 2024 DAVA Summit on Genitourinary Malignancies. Our morning session agenda is packed with engaging presentations and pioneering research. Join in through our virtual platform!”

Nitin Vaishampayan delves into the PEACE-3 trial:

“Dr. Nitin Vaishampayan delves into the PEACE-3 trial, a Phase III study evaluating enzalutamide alone vs its combination with radium-223 in asymptomatic/mildly symptomatic mCRPC patients with bone metastases.”

Charles Nguyen discussed the role of immunotherapy in non-clear cell RCC:

“Dr Charles Nguyen from City of Hope Orange County discussed the role of immunotherapy in non-clear cell RCC, covering pembrolizumab (KN-427, Cohort B), SUNNIFORECAST (ipilimumab/nivolumab, IO/TKI combinations), and ongoing IO/TKI studies like FORTUNE (tivozanib + nivolumab)”

David Einstein about EMBARK trial:

“EMBARK trial evaluating enzalutamide + leuprolide and enzalutamide monotherapy vs. leuprolide alone in high-risk biochemical recurrence prostate cancer discussed by Dr. David Einstein from BIDMC.”

Exploring the future of GU cancer care:

“Grateful to all the faculty who have joined us in Broadmoor this week! DAVA GU is off to an amazing start. Excited for two more days of insightful discussions and exploring the future of GU cancer care.”

Day 3 of the 2024 DAVA Summit:

“Rise and shine from Broadmoor! Our morning agenda on Day 3 is packed with exciting topics, including checkpoint inhibitors in urothelial carcinoma, metastatic castration-resistant prostate cancer and more. Join in through our virtual platform!”

Thought-provoking talk by Alicia Morgans:

“Dr. Alicia Morgans from Dana-Farber Cancer Institute delivers a thought-provoking talk on integrating quality of life data into decision-making for prostate cancer treatment. A vital step towards patient-centered care, balancing treatment efficacy with life quality.”

Michael Haffner’s insights on molecular heterogeneity in mPC:

“In his presentation, Dr. Michael Haffner from Fred Hutchinson Cancer Center shared insights on molecular heterogeneity in metastatic prostate cancer, exploring clinical translation opportunities and augmenting PSMA-directed therapy through epigenetic priming”

Benjamin Garmezy presents Mevrometostat:

“Dr. Benjamin Garmezy presents Mevrometostat, an EZH2 inhibitor, showing promise in mCRPC. The Phase 1 study highlights its potential in combination with enzalutamide for treating castration-resistant prostate cancer.”

Final Day of 2024 DAVA Broadmoor GU Summit:

“Good morning from Broadmoor! Join us for our final morning sessions where we dive deep into groundbreaking presentations and discussions on the latest advancements in genitourinary malignancies. Thank you for being part of the 2024 DAVA Broadmoor GU Summit!”

Maria Carlo Explored the impact of Birt-Hogg-Dubé syndrome:

“Exploring the impact of Birt-Hogg-Dubé syndrome and BAP1 mutations in RCC and beyond: Dr. Maria Carlo from M SKCCdelves into the relevance of these genetic factors in cancer development and treatment.”

Scott Eggener presents the Stockholm3 (STHLM3) test:

“Dr. Scott Eggener presents the Stockholm3 (STHLM3) test, a blood-based biomarker that improves prostate cancer screening by reducing unnecessary biopsies and detecting high-risk cancers. The test shows promising results across diverse racial and ethnic groups.”

Matthew Dallos presents the NeoRED-P study:

“Dr. Matthew Dallos presents the NeoRED-P study, focusing on neoadjuvant immunotherapy in high-risk localized prostate cancer. Study will allow to understand the biology and test the feasibility of immunotherapy in the neoadjuvant setting.”

More posts featuring DAVA Oncology